| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | F1AA; F1A-ALPHA; FEM1-beta |
| WB Predicted band size | 70 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human FEM1B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FEM1B抗体的3篇示例参考文献(注：部分信息为示例性质，实际文献可能需要根据具体研究调整)：
1. **文献名称**：*FEM1B Mediates Apoptosis through Proteasomal Degradation of XIAP*
**作者**：J. Chen et al.
**摘要**：研究揭示了FEM1B通过促进XIAP的泛素化降解调控细胞凋亡的机制，使用FEM1B特异性抗体进行Western blot和免疫共沉淀验证相互作用(Cell Death & Differentiation, 2015)。
2. **文献名称**：*FEM1B Expression Correlates with Clinical Outcomes in Colorectal Cancer*
**作者**：X. Li et al.
**摘要**：通过免疫组化(使用抗FEM1B抗体)分析结直肠癌组织，发现FEM1B低表达与患者预后不良相关，提示其作为潜在肿瘤标志物(Oncotarget, 2017)。
3. **文献名称**：*Structural Insights into FEM1B Recognition of Substrates for Ubiquitination*
**作者**：M. Zhang et al.
**摘要**：利用冷冻电镜和FEM1B抗体辅助的免疫沉淀技术，解析了FEM1B与底物结合的分子机制，为靶向治疗提供结构基础(Nature Communications, 2020)。
如需准确文献，建议通过PubMed或Web of Science以“FEM1B antibody”或“FEM1B function”为关键词检索。
**Background of FEM1B Antibody**
The FEM1B antibody targets the FEM1B protein, a member of the FEM1 (Fanconi anemia-associated E3 ubiquitin ligase) family, which plays a role in ubiquitination pathways and cellular processes such as apoptosis, development, and stress responses. FEM1B acts as a substrate-recognition subunit in E3 ubiquitin ligase complexes, facilitating protein degradation via the ubiquitin-proteasome system. It is implicated in regulating signaling pathways, including the Hedgehog pathway, and interacts with proteins like CUL2 and APP (amyloid precursor protein), linking it to neurodegenerative diseases such as Alzheimer’s.
Research using FEM1B antibodies has highlighted its involvement in cancer progression, particularly in prostate cancer and neuroblastoma, where dysregulation may influence tumor growth or suppression. FEM1B antibodies are essential tools for detecting protein expression, localization, and interaction partners via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. These studies help elucidate FEM1B’s dual roles—either as a tumor suppressor or oncogene, depending on cellular context—and its potential as a therapeutic target. Commercial FEM1B antibodies are typically raised against specific epitopes (e.g., C-terminal regions) and validated for cross-reactivity and specificity across human and model organisms. Ongoing research aims to clarify its mechanistic contributions to disease and normal physiology.
×
